MTX-531
PIK3CA-mutant solid tumors (e.g., head and neck, breast, lung, gastrointestinal)
PreclinicalActive
Key Facts
Indication
PIK3CA-mutant solid tumors (e.g., head and neck, breast, lung, gastrointestinal)
Phase
Preclinical
Status
Active
Company
About MEKanistic Therapeutics
MEKanistic Therapeutics is a private, preclinical biotech focused on overcoming treatment resistance in PIK3CA-mutant cancers. Its core strategy involves designing small molecules that simultaneously inhibit primary oncogenic drivers and key adaptive resistance pathways, as exemplified by its lead dual PI3K/EGFR inhibitor, MTX-531. The company has been selected for the NCI's NExT program to accelerate development and is led by a seasoned team with deep experience in kinase biology, drug discovery, and clinical development. MEKanistic aims to deliver more durable responses and a better safety profile compared to existing targeted therapies.
View full company profile